The relevance of heart failure severity for treatment with evidence-based pharmacotherapy in general practice by Pont, LG et al.
  
 University of Groningen
The relevance of heart failure severity for treatment with evidence-based pharmacotherapy in
general practice
Pont, LG; van Gilst, WH; Lok, DJA; Kragten, HJA; Haaijer-Ruskamp, FM; Dutch Working
Group Heart Failure
Published in:
European Journal of Heart Failure
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2003
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Pont, LG., van Gilst, WH., Lok, DJA., Kragten, HJA., Haaijer-Ruskamp, FM., & Dutch Working Group Heart
Failure (2003). The relevance of heart failure severity for treatment with evidence-based pharmacotherapy
in general practice. European Journal of Heart Failure, 5(2), 187-193. [PII S1388-9842(02)00202-7].
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
The European Journal of Heart Failure 5 (2003) 187–193
1388-9842/03/$ - see front matter  2002 European Society of Cardiology. Published by Elsevier Science B.V. All rights reserved.
PII: S1388-9842Ž02.00202-7
The relevance of heart failure severity for treatment with evidence-based
pharmacotherapy in general practice
Lisa G. Pont *, Wiek H. van Gilst , Dirk J.A. Lok , Hans J.A. Kragten , Flora M. Haaijer-Ruskamp ,a, a b c a
on behalf of the Dutch Working Group on Heart Failure
Department of Clinical Pharmacology, University of Groningen, Ant. Deusinglaan 1, 9713 AV, Groningen, The Netherlandsa
Department of Cardiology, Deventer Hospital, Deventer, The Netherlandsb
Department of Cardiology, Atrium Medical Centre, Heerlen, The Netherlandsc
Received 18 March 2002; received in revised form 23 July 2002; accepted 3 October 2002
Abstract
Aims: Internationally, research indicates that pharmacotherapy for chronic heart failure (CHF) is sub-optimal. Traditionally,
assessment of drug use in heart failure has focused on the use of individual agents irrespective of CHF severity. This study
investigates drug use for CHF patients in general practice with respect to the available evidence, incorporating both disease
severity and the use of combination drug regimes. Methods and results: A cross-sectional survey of 769 Dutch CHF patients was
performed as part of IMPROVEMENT of HF study. For each New York Heart Association severity classification the minimum
treatment appropriate for the heart failure severity according to the scientific evidence available at the time of the study (1999)
was defined. The proportion of patients treated with each drug increased with increasing severity, with the exception of the b-
blockers. Patients with less severe heart failure were approximately four to eight times more likely to receive evidence-based
treatment than those with more severe heart failure. Discussion: To assess pharmacological treatment of heart failure, in relation
to the available evidence, it is important to take severity into account. While the number of drugs prescribed increased with
increasing severity, the use of evidence-based regimes was lower in patients with more severe heart failure.
 2002 European Society of Cardiology. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Chronic heart failure (CHF) is an increasingly impor-
tant health care issue affecting almost 4% of the popu-
lation aged over 55 years and up to 13% of those aged
over 75 w1x. With the aging population, the prevalence
of heart failure is rising and unlike other cardiovascular
conditions, morbidity is increasing w2x. The majority of
heart failure patients are managed in general practice
w2x, thus knowledge regarding GP management of heart
failure is essential. Pharmacological treatment is an
important aspect of heart failure management and in the
past decade, the management of heart failure has under-
gone major change. Major studies have demonstrated
*Corresponding author. Tel.: q61-2-96994499; fax: q61-2-
96995155.
E-mail address: l.pont@nps.org.au (L.G. Pont).
the benefits of ACE inhibitors (ACEI) w3,4x, b-blockers
w5x and spironolactone w6x in improving the prognosis
of heart failure patients. Current research indicates inter-
nationally that pharmacotherapy for heart failure is sub-
optimal w2,7x and lags behind the current evidence.
While the under-use of ACEIs for heart failure has
been well-documented w8,9x, little is known about the
use of other drugs in the daily practice. To date,
investigation into heart failure pharmacotherapy has
focused on the use of single agents w10,11x without
taking heart failure severity into account. However,
optimal heart failure treatment differs depending on the
heart failure severity, and usually involves combination
therapy. The aim of this study is to investigate the
pharmacological treatment of heart failure in general
practice with respect to the available evidence, incor-
porating both disease severity and the use of combina-
tion therapy.
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Table 1
Patient characteristics
Mean age years (S.D.) 71.6 (12.3)
% female 40.1
Severity Number (%)
NYHA 1 134 (17.4)
NYHA 2 253 (32.9)
NYHA 3 232 (30.2)
NYHA 4 150 (19.5)
Comorbidity
Hypertension 313 (40.7)
Atrial fibrillation 185 (24.1)
Myocardial infarction 271 (36.0)
2. Methods
2.1. Study population
This study was part of the IMPROVEMENT of HF
(Improvement program on evaluation and management
of heart failure) study, an initiative developed to increase
awareness and management of heart failure among
primary care physicians throughout Europe w12x. A
sample of Dutch general practitioners (ns78) stratified
by practice location to be representative of the Dutch
situation, were invited to participate in the study. Each
general practitioner registered all heart failure patients
seen during a 6-week period in 1999y2000. A random
selection of up to 10 of these patients per prescriber
was included in the study. Trained research assistants
abstracted data on selected cardiovascular comorbidities,
clinical status and current medication use from patients’
medical records. Heart failure severity according to the
New York Heart Association (NYHA) classification was
determined by each patient’s GP.
2.2. Minimum evidence-based treatment
For each NYHA classification a minimum evidence-
based treatment regime was defined. These regimes
represent the basic minimum treatment for heart failure
a patient with a particular heart failure severity should
receive according to the evidence current at the time of
the study in 1999y2000. While additional agents such
as digoxin or spironolactone may be indicated for some
patients within each severity classification, all patients
could expect treatment with, at least, the minimum
regimes. For NYHA 1 and 2 the minimum evidence-
based heart failure treatment was defined as an ACEI,
either as monotherapy or in combination with other
agents. A combination regime including both an ACEI
and a b-blocker was defined as the minimum evidence-
based regime for NYHA 3 and 4. Again this can be in
combination with other agents as needed by the individ-
ual patient. Since it could be expected that angiotensin
II antagonists (AIIA) could be used instead of an ACEI
in some patients w13x, we treated both agents together
throughout this study, thus where ever we use the term
ACEI we have included both ACEI and AIIA.
2.3. Analysis
The primary objective of this study was to determine
if heart failure patients managed in general practice were
receiving evidence-based treatment. For each NYHA
severity classification the number of patients with treat-
ment corresponding to that defined above as the mini-
mum evidence-based treatment was determined. Odds
ratios associated with receiving at least the minimum
evidence-based treatment were calculated for each
NYHA class.
To gain further insight into the pharmacological treat-
ment of heart failure patients in general practice, we
determined the proportion of heart failure patients treated
with different combination drug regimes. These combi-
nations incorporated the drug groups for which at the
time of the study, evidence existed of their benefit in
the treatment of heart failure. Despite the lack of
evidence from large clinical trials for the use of diuretics
in heart failure, given their well-established and accepted
role in the treatment of heart failure, we included this
group in the different combination regimes studied.
3. Results
3.1. Study population
In total, data from 769 patients registered with 78
GPs were included in the study. The mean number of
patients per GP was 9.9. Mean patient age was 71.5
years and 59.9% of the heart failure patients were male
(Table 1). NYHA classification was recorded for almost
all patients (94.5%). Patient characteristics are presented
in Table 1.
3.2. Medication use
Looking simply at the use of the individual drug
groups diuretics were the most commonly used drug
group, used by 66.8% of the patients (Table 2). The
proportion of patients treated with each drug group
increased with increasing NYHA classification, with the
exception of the b-blockers. The use of the latter
decreased with increasing heart failure severity. Of the
patients with NYHA class 1 heart failure 51.5% were
being treated with a b-blocker while in NYHA class 4
this was only 23.3%. As expected, AIIA appeared to be
used as an alternative to ACEIs in most patients using
either of these drug groups. Only a small proportion of
patients (0.7%), were using both an ACEI and an AIIA
simultaneously.
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Table 2
Use individual drug groups by heart failure patients. Results presented as percentage of patients (95% confidence intervals)
NYHA 1 NYHA 2 NYHA 3 NYHA 4 Total
(ns134) (ns235) (ns232) (ns150) (ns796)
Diuretic 29.9 57.3 81.9 92.7 66.8
(22.1–37.6) (51.2–63.4) (76.9–86.9) (88.5–96.8) (63.5–70.2)
ACEI 41.0 57.7 66.8 69.3 59.9
(32.7–49.4) (52.0–64.2 (60.8–72.9) (62.0–76.7) (56.5–63.4)
b-blocker 51.5 42.3 36.2 23.3 38.4
(43.0–60.0) (36.2–48.4) (30.0–42.4) (16.6–30.1) (34.9–41.8)
Digoxin 11.9 20.2 34.9 37.3 26.5
(6.4–17.4) (15.2–25.1) (28.8–41.0) (29.6–45.1) (23.4–29.6)
Spironolactone 4.5 7.5 15.9 30.0 13.9
(1.0–8.0) (4.3–10.8) (11.2–20.7) (22.7–37.3) (11.5–16.4)
Table 3
Minimum evidence-based treatment: percentage of heart failure patients treated with the minimum evidence-based regime per NYHA classa
Severity Minimum Crude odds ratio Adjusted odds ratios (ageysex) Percentage of patients
evidence-based (95% confidence interval) (95% confidence interval) (95% confidence interval)
treatment regime
NYHA 1 ACEI 3.8 3.8 41.0
(ns134) (2.2–6.7) (2.1–6.7) (32.7–49.4)
NYHA 2 ACEI 7.7 7.8 57.7
(ns253) (4.6–12.7) (4.6–13.0) (52.0–64.2)
NYHA 3 ACEIqb-blocker 1.6 1.6 22.4
(ns232) (0.9–2.7) (0.9–2.8) (17.0–27.8)




Other cardiovascular drug treatments in addition to the minimum evidence-based regime may have been used.a
3.3. Cardiovascular comorbidity and medication use
Coexisting atrial fibrillation was present in 24.1%
(ns185y796) of the participating patients. Digoxin was
prescribed to 58.3% (ns108y185) of these patients. Of
all digoxin users, 52.9% (ns108y204) of patients had
coexisting atrial fibrillation. b-blockers were prescribed
to 295 (38.4%) heart failure patients. Less than half of
these patients had a past history of MI (45.4%, ns134y
295) or coexisting hypertension (45.8%, ns135y295).
Just over 50% (50.6%, ns137y271) of heart failure
patients with a history of MI were not treated with a b-
blocker. The majority of heart failure patients with
coexisting hypertension were treated with a diuretic
(71.6%, ns224y313) andyor an ACEI (73.8% ns231y
313). However, hypertension was present among less
than half of all diuretic users (43.6%, 224y514) and
just over half of all ACEI users (50.2%, 321y2460).
3.4. Minimum evidence-based treatment
As NYHA heart failure severity class increased, the
proportion of patients receiving the minimum evidence-
based regime suitable for their severity class decreased
(Table 3). After adjustment for age and sex, patients
with less severe heart failure (NYHA classes 1 and 2)
were approximately four to eight times more likely to
receive evidence-based treatment than those with more
severe heart failure (NYHA class 3 and 4).
3.5. Combination regimes
As expected, the use of combination therapy increased
as disease severity increased (Table 4). Of the patients
classified as NYHA heart failure class 1, the majority
were treated with monotherapy (35.8%), 26.1% were
being treated with a combination regime consisting of 2
or more of the drug groups investigated and 12.7% were
being treated with a combination of 3 different agents.
Just under a quarter of NYHA class 1 patients (22.4%)
were not receiving any of the drug groups included in
this study.
Over 60% of NYHA class 2 heart failure patients
were being treated with a combination regime. For the
190 L.G. Pont et al. / The European Journal of Heart Failure 5 (2003) 187–193
majority of NYHA class 2 patients a combination of
two drug groups was used (34.4%). Overall, the most
common combination among NYHA class 2 patients
(13.4%) was a diuretic and ACEI. The majority of
NYHA class 3 patients received were also treated with
a combination consisting of two agents and again the
combination of an ACEI and a diuretic was the most
commonly used (18.7%). Among the most severe heart
failure patients (NYHA class 4) the majority were
prescribed a regime consisting of three different drug
groups. Again, among NYHA class 4 patients, the most
common individual regime was the combination of an
ACEI and a diuretic (18.7%).
4. Discussion
Overall, the number of heart failure patients receiving
at least the minimum evidence-based treatment recom-
mended for their heart failure severity defined in this
study was low (36.0%). We observed that patients with
more severe heart failure are less likely to be receiving
evidence-based treatment in general practice than
patients with less severe heart failure. When stratified
for age, sex and NYHA severity class, patients with less
severe heart failure were approximately four to eight
times more likely to be receiving an evidence-based
treatment than patients in NYHA severity classes 3 or
4.
We defined minimum evidence-based treatment
regimes based on the evidence current at the time of the
study. Evidence regarding the benefits of ACEI on both
symptoms and mortality in heart failure first emerged in
the late 1980s w3,14x and these agents were considered
first-line treatment for all heart failure patients at the
time of this study w15x. The role of b-blockers in the
treatment of heart failure had also been established
w16,17x. Thus, treatment with a b-blocker was included
in our definition of minimum evidenced-based treatment
for NYHA class 3 and 4. While digoxin has a clear role
in the treatment of heart failure in a subgroup of patients,
that is in those with coexisting atrial fibrillation, it was
not considered an essential drug for the treatment of all
heart failure patients of a particular severity class w15x.
Similarly, there was evidence supporting the use of
spironolactone in the treatment of heart failure for some
patients w6x but this was in the role of an add-on therapy
and not as a basic treatment w15x. If spironolactone or
digoxin were included in the minimum evidence-based
regime definition it is expected that the number of
patients receiving the minimum recommended treatment
would be even lower.
Assessment of pharmacotherapy for heart failure gen-
erally focuses on use of different drug groups w8,18–
21x among all heart failure patients irrespective of their
disease severity. In this study we observed, with the
exception of the b-blockers, that the proportion of
patients treated with each agent increased with increas-
ing heart failure severity. Among all heart failure
patients, irrespective of their severity level ACEI use
was lower than expected. However, when drug use was
stratified for NYHA severity class it became apparent
that the lower use among patients in NYHA severity
class 1 decreases the mean percentage of patients treated
with an ACEI, and that ACEI use among patients with
more severe heart failure was higher. In contrast, the
percentage of heart failure patients treated with a b-
blocker decreased in the more severe patients, which is
not evident when simply looking at the total number of
patients prescribed a b-blocker irrespective of heart
failure severity. These findings underline the relevance
of including a measure of heart failure severity in any
assessment of pharmacotherapy quality.
Similarly, the majority of studies until now, focus on
the prescribing of individual agents and not on combi-
nations of these drug groups. Among our patient popu-
lation the majority of patients (60.2%) were being
treated with a combination of at least 2 different drug
groups. Comparing Tables 2 and 4 show the value of
including drug combinations in an assessment of pre-
scribing quality. When looking at the individual agents,
the majority of patients use diuretics or ACEI (66.8%
and 59.9%, respectively). However, diuretics were used
in combination with an ACEI in only 42.6% of all
patients, despite the current ESC guideline recommen-
dations that diuretics should always be used in combi-
nation with an ACEI. Since optimal heart failure therapy
for most patients especially those with more severe heart
failure consists of a combination of different agents
w15x, looking simply at the use of individual agents for
the treatment of heart failure may overestimate the
quality of evidence-based treatment for heart failure.
For this work, patient data was abstracted from the
GPs medical records. These records contain complete
information on each patient’s current pharmacotherapy.
Common to most studies investigating cardiovascular
pharmacotherapy the problem is that the medications
may be used for multiple cardiovascular indications. In
this study we have assumed that a heart failure patient
treated with a medication commonly associated with the
treatment of heart failure would have been prescribed
that medication for their heart failure since an indication
is not generally available for each medication. Given
the high prevalence of cardiovascular comorbidities
among these patients it is possible that the medications
included in this work were used for indications other
than heart failure. From the GP records it is not generally
possible to determine who initiated each medication: the
GP or a specialist. Furthermore, medications supplied
solely by a specialist may not be recorded in the patient’s
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Table 4
Combination regimes: percentage patients per NYHA treated with the major treatment regimes containing diuretics, ACEI, b-blockers, digoxin
or spironolactonea
NYHA 1 NYHA 2 NYHA 3 NYHA 4 All heart failure patients
None 22.4 8.3 0.9 0.7 7.0
(15.3–29.4) (4.9–11.7) (0.2–3.1) (0.1–3.7) (5.2–8.8)
Diuretic monotherapy 3.7 8.7 9.9 10.7 8.6
(0.5–6.9) (5.2–12.2) (6.1–13.8) (5.7–15.6) (6.4–10.2)
ACEI monotherapy 8.2 8.7 3.0 0.7 5.3
(3.6–12.9) (5.2–12.2) (0.8–5.2) (0.1–3.7) (3.7–6.9)
b-blocker monotherapy 23.1 11.5 4.7 2.0 9.6
(16.0–30.3) (7.5–15.4) (2.0–7.5) (0.7–5.7) (7.5–11.7)
Diuretic and ACEI 3.7 13.4 21.1 18.7 15.1
(0.5–6.9) (9.2–17.6) (15.9–26.4) (12.4–24.9) (12.6–17.6)
Diuretic and b-blocker 6.0 5.9 4.7 2.0 4.8
(2.0–10.0) (3.0–8.8) (2.0–7.5) (0.7–5.7) (3.3–6.3)
Diuretic and digoxin 0.7 3.2 4.7 5.3 3.6
(0.1–4.1) (1.0–5.3) (2.0–7.5) (1.7–8.9) (2.3–5.0)
ACEI and b-blocker 15.7 9.1 3.9 0.7 7.0
(9.5–21.8) (5.5–12.6) (1.4–6.4) (0.1–3.7) (5.2–8.8)
Diuretic and ACEI and b-blocker 3.0 9.5 8.2 7.3 7.5
(1.2–7.4) (5.9–13.1) (4.7–11.7) (3.2–11.5) (5.7–9.4)
Diuretic and ACEI and digoxin 6.0 7.5 11.2 14.7 9.8
(2.0–10.0) (4.3–10.8) (7.1–15.3) (9.0–20.3) (7.7–11.8)
Diuretic and ACEI and spironolactone 1.5 2.0 3.9 10.7 4.2
(0.4–5.3) (0.3–3) (1.4–6.4) (5.7–15.6) (2.7–7.6)
Diuretic and ACE and b-blocker and digoxin 1.5 1.6 6.0 3.3 3.3
(0.4–5.3) (0.6–4.0) (3.0–9.1) (0.5–6.2) (2.0–4.5)
Diuretic and ACEI and digoxin and spironolactone 0 1.2 3.4 6.7 2.7
(0.4–3.4) (1.1–5.8) (2.7–10.7) (1.6–3.9)
Otherb 4.5 9.4 14.4 16.5 11.5
(1.0–8.0) (5.9–13.1) (9.7–18.7) (10.7–22.6) (9.2–13.7)
Total 100 100 100 100 100
(ns134) (ns252) (ns232) (ns150) (ns769)
Other cardiovascular agents in addition to those included in this table may have been used. Ninety-five percent confidence intervals area
presented in parentheses.
Other combinations not shown in the table were used by less than 5% of heart failure patients in each NYHA class.b
general practice records. However, in the Netherlands,
patient’s prescribed a new medication by a specialist
return to their GP for further supply of the medication
indicating that continual supply by the specialist is the
exception.
A number of reasons could explain the low percentage
of patients treated with at least the minimum evidence-
based regime. Important in the use of any drug are the
associated contraindications and side effects. Contrain-
dications or poor tolerance are valid reasons for not
using a drug group recommended in the evidence in an
individual patient. Another factor that may contribute to
the low percentage of patients receiving the minimum
recommended treatment are the differences that exist
between the clinical trial heart failure population and
the general practice heart failure population w22x. The
heart failure patients treated in general practice are
generally older and have more comorbidities than the
clinical trial heart failure population.
Under-use of ACEI in the treatment of heart failure
has been extensively studied and barriers to optimal
ACE use centre around GP concerns regarding side
effects namely hypotension, renal insufficiency and
cough w23,24x. Little work has been done on the barriers
associated with optimal use of the other agents in the
treatment of heart failure. In this study we see that while
overall use of ACEI is approximately 60% in the most
severe patients, it is higher at 70%. The most common
reason among patients with class 3 and 4 heart failure
for sub-optimal treatment was the lack of a b-blocker.
The role of b-blockers has undergone major change in
the past decade. Until the publication of new clinical
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trials in the mid-1990s b-blockers were traditionally
considered contraindicated for heart failure patients and
this changing role may explain their low use in general
practice for the treatment of heart failure. At the time
of this study, the Copernicus study showing the benefits
of b-blockers in stable NYHA class 4 patients had not
yet been published w25x, which could be one factor
contributing to the low use of b-blockers among patients
with severe heart failure.
To assess the pharmacological treatment of heart
failure in relation to the available evidence, it is impor-
tant to take severity into account. While the number of
drugs prescribed per heart failure patient increased with
increasing severity, the use of evidence-based regimes
was lower among patients with more severe heart failure
(NYHA 3 and 4). Overall prescribing of ACEI was low,
however, use increased among patients with more severe
heart failure. While the use of ACEI increased with
increasing CHF severity, this was not the case for the
b-blockers. Prescribing of b-blockers clearly decreased
as CHF severity increased. Furthermore, prescribing of
b-blockers among all patients was low. This shows that
while the evidence regarding the use of ACEI in the
treatment of CHF has started to reach general practition-
ers, the message regarding the use of b-blockers in the
treatment of CHF is yet to penetrate. One of the next
steps towards improving heart failure management is to
investigate the reasons underlying the low use of b-
blockers in general practice and then to address these
issues with educational programs. Such programs are
clearly needed to improve heart failure management in
general practice and should give special consideration
to the role of b-blockers in the treatment of CHF.
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